COVID-19疫苗相关的筛查乳腺X线摄影上亚临床腋窝淋巴结病
该研究纳入1027例接受筛查乳腺X线摄影的女性,评估接种Pfizer-BioNTech或Moderna COVID-19疫苗后亚临床单侧腋窝淋巴结病的发生率。接种疫苗者发生率为13.2%(Pfizer)和9.5%(Moderna),未接种者为1.2%,且淋巴结病平均在末次接种后46.5天消退。作者建议可在接种前安排筛查或推迟筛查8周。
要点
- 接种mRNA COVID-19疫苗后筛查乳腺X线摄影可显示亚临床单侧腋窝淋巴结病,可能被误认为恶性。
- Pfizer疫苗接种者亚临床腋窝淋巴结病发生率为13.2%,Moderna为9.5%,未接种者为1.2%。
- 淋巴结病平均在末次接种后46.5天消退(Pfizer 50.7天,Moderna 41.5天)。
核心结论
- 接种COVID-19疫苗后行筛查乳腺X线摄影的女性出现亚临床单侧腋窝淋巴结病的可能性显著高于未接种者,作者建议可在接种前安排筛查或考虑推迟筛查8周。
研究设计与样本
- IRB批准、符合HIPAA的研究,2020年12月14日至2021年4月14日期间1027例符合纳入标准的筛查乳腺X线摄影患者,排除有基线淋巴结病或既往癌症诊断者。
关键影像表现/征象
- 筛查乳腺X线摄影上表现为亚临床单侧腋窝淋巴结病。
- 43例因单侧亚临床腋窝淋巴结病被召回,其中34例接种了同侧COVID-19疫苗(Pfizer n=19,44.2%;Moderna n=15,34.9%),9例未接种(20.9%)。
诊断标准与关键数值
- 接种Pfizer疫苗者亚临床腋窝淋巴结病发生率为13.2%,接种Moderna疫苗者为9.5%,未接种者为1.2%。
- 在筛查乳腺X线摄影前约7周内接种COVID-19疫苗者,单侧腋窝亚临床淋巴结病发生率显著更高(p值<0.01)。
- 淋巴结病在诊断性乳腺X线摄影上的平均消退时间总体为46.5天,Pfizer为50.7天,Moderna为41.5天。
- Moderna疫苗在老年女性中引起更强的反应(Moderna 63.7岁 vs. Pfizer 59.7岁)。
- 对于两种疫苗,亚临床腋窝淋巴结病在末次COVID-19疫苗接种后平均46.5天消退(p=0.44)。
临床应用与阅片要点
- 作者建议,接种mRNA COVID-19疫苗的女性可在接种前安排筛查乳腺X线摄影,或考虑将筛查乳腺X线摄影推迟8周。
- 作者认为Pfizer疫苗可能总体免疫反应更强,而Moderna疫苗可能在老年女性中引起更强的免疫反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Women who received a COVID-19 vaccination may display subclinical unilateral axillary lymphadenopathy on screening mammography, which can appear suspicious for malignancy, leading to additional diagnostic evaluation.
PURPOSE: To evaluate the prevalence of subclinical unilateral axillary lymphadenopathy (sLAD) on screening mammogram in women who received either the first or second dose of the Pfizer-BioNTech (Pfizer) or Moderna COVID-19 vaccines compared to women who have not.
MATERIALS AND METHODS: In this IRB-approved, HIPAA complaint study from 12/14/2020 to 4/14/2021, 1027 patients presented for screening mammography and met study inclusion criteria. Patients with history of baseline lymphadenopathy or prior cancer diagnosis were excluded.
RESULTS: Of the 1027 women, 43 were recalled for unilateral sLAD. 34 women received a COVID-19 vaccination ipsilateral to the sLAD (Pfizer n=19, 44.2%; Moderna n=15, 34.9%), 9 did not (20.9%). Incidence of unilateral axillary sLAD was significantly higher (p-value<0.01) in those who received a COVID-19 vaccination within approximately 7 weeks preceding screening mammogram. 13.2% of patients who received the Pfizer vaccine and 9.5% of patients who received the Moderna vaccine developed sLAD. Moderna's vaccine elicited a more robust reaction in the elderly (Moderna 63.7 years vs. Pfizer 59.7 years). For both vaccines, sLAD resolved on average 46.5 days after the last COVID-19 vaccine (p=0.44).
CONCLUSION: Women who have received either mRNA COVID-19 vaccines may benefit from scheduling their screening mammogram before vaccination or consider delaying screening mammography 8 weeks. While Pfizer may have an overall more robust immune response, Moderna may elicit a stronger immune response in elderly women.
SUMMARY: Women who received a COVID-19 vaccination before screening mammography were significantly more likely to present with subclinical axillary lymphadenopathy than women who did not receive the vaccine.
KEY RESULTS: 13.2% of women who received a Pfizer-BioNTech vaccine exhibited subclinical axillary lymphadenopathy compared to 9.5% of those who received the Moderna vaccine. Only 1.2 % of those who did not receive a vaccine presented with subclinical unilateral axillary lymphadenopathy. The average time of resolution of the lymphadenopathy on diagnostic mammogram was 46.5 days overall, with Pfizer-BioNTech taking 50.7 days and Moderna 41.5 days.
引用
- Raj, Ogola, Han, et al. COVID-19 Vaccine-Associated Subclinical Axillary Lymphadenopathy on Screening Mammogram. Acad Radiol. 2021. PMID: 34906409. doi:10.1016/j.acra.2021.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。